+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension



First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension



European Respiratory Journal 51(3)




(PDF emailed within 0-6 h: $19.90)

Accession: 065153760

Download citation: RISBibTeXText

PMID: 29348153

DOI: 10.1183/13993003.01694-2017


Related references

Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. American Heart Journal 162(3): 562-568, 2011

SAT0015Increased Concentrations of CCL5, PDF-AA and PDGF-BB are Associated with Irreversible Vascular Remodeling of the Pulmonary Circulation in Interstitial Lung Disease Associated Pulmonary Arterial Hypertension. Annals of the Rheumatic Diseases 74(Suppl 2): 654.3-655, 2015

Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension. International Journal of Cardiovascular Imaging 2019, 2019

Other causes of pulmonary arterial hypertension: pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, porto-pulmonary hypertension, HIV- associated pulmonary arterial hypertension. Anadolu Kardiyoloji Dergisi 10 Suppl 1: 63-68, 2010

Dasatinib-induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology 84(5): 835-845, 2018

Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. American Journal of Pathology 174(2): 380-389, 2009

Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension. Circulation 131(23): 2079-2091, 2015

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulmonary Circulation 7(4): 803-807, 2017

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. European Respiratory Journal 42(3): 869-870, 2014

Niflumic Acid Attenuated Pulmonary Artery Tone and Vascular Structural Remodeling of Pulmonary Arterial Hypertension Induced by High Pulmonary Blood Flow In Vivo. Journal of Cardiovascular Pharmacology 66(4): 383-391, 2016

Regulatory role of calcium activated chloride channel in pulmonary vascular structural remodeling in rats with pulmonary arterial hypertension induced by high pulmonary blood flow. Zhonghua Er Ke Za Zhi 54(9): 692-697, 2017

Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102 Suppl 2: Ii30-Ii35, 2016

Dasatinib-induced pulmonary arterial hypertension - A rare late complication. Journal of Oncology Pharmacy Practice 2018: 1078155217753740, 2018

Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 122(2): 524-527, 2002

Experimental studies of pulmonary hypertension--correlation between pulmonary arterial pressure and histopathological changes of the pulmonary vasculature. Nihon Kyobu Shikkan Gakkai Zasshi 14(9): 494-505, 1976